Skip to main content

Table 4 The correlation of CDK5 with diverse clinical clinicopathological factors in NSCLC

From: An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker

NSCLC n CDK5 negative (n, %) CDK5 positive (n, %) Z P
Gender     −0.406 0.685
 Male 254 126(49.6) 128(50.4)   
 Female 85 40(47.1) 45(52.9)   
Age(years)     −0.080 0.936
 <60 181 89(49.2) 92(50.8)   
 ≥60 158 77(48.7) 81(51.3)   
Pathological grading     24.58a <0.001
 I 39 29(74.4) 10(25.6)   
 II 92 53(57.6) 39(42.4)   
 III 130 44(33.8) 86(66.2)   
TNM     −2.376 0.018
 I–II 286 148(51.7) 138(48.3)   
 III–IV 53 18(34.0) 35(66.0)   
LNM     −6.717 <0.001
 Yes 115 27(23.5)) 88(76.5)   
 No 224 139(62.1) 85(37.9)   
Tumor diameter (cm)     −1.145 0.252
 ≤7 295 148(50.2) 147(49.8)   
 >7 44 18(40.9) 26(59.1)   
Distal metastasis     −1.962 0.05
 Absent 323 162(50.2) 161(49.8)   
 Present 16 4(25.0) 12(75.0)   
Histology     3.646a 0.456
 Adenocarcinoma 127 64(50.4) 63(49.6)   
 Squamous cell carcinoma 175 88(50.3) 87(49.7)   
 Adenosquamous carcinoma 28 10(35.7) 18(64.3)   
 Undifferentiated carcinoma 8 3(37.5) 5(62.5)   
 Large cell carcinoma 1 1(100) 0(0)   
Adenocarcinoma classification     6.508a 0.089
 Acinar adenocarcinoma 83 36(43.4) 47(56.6)   
 Papillary adenocarcinoma 19 12(63.2) 7(36.8)   
 Broncholoalveolar cell carcinoma 18 10(55.6) 8(44.4)   
 Mucinous carcinoma 7 6(85.7) 1(14.3)   
  1. Pathological grading I vs. II Z = −1.805, P = 0.071, I vs. III Z = −4.466, P < 0.001, II vs. III Z = −3.508, P < 0.001. Acinar adenocarcinoma vs. mucinous Z = −2.144, P = 0.032. There were no differences of expression of CDK5 in other subgroups
  2. aKruskal-Wallis H test was performed when the data were divided into more than two groups